vs

Side-by-side financial comparison of TScan Therapeutics, Inc. (TCRX) and WRAP TECHNOLOGIES, INC. (WRAP). Click either name above to swap in a different company.

TScan Therapeutics, Inc. is the larger business by last-quarter revenue ($2.6M vs $1.4M, roughly 1.8× WRAP TECHNOLOGIES, INC.). WRAP TECHNOLOGIES, INC. runs the higher net margin — -280.9% vs -895.1%, a 614.2% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs 62.3%). WRAP TECHNOLOGIES, INC. produced more free cash flow last quarter ($-2.7M vs $-32.2M). Over the past eight quarters, WRAP TECHNOLOGIES, INC.'s revenue compounded faster (-2.5% CAGR vs -9.7%).

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

Wrap Technologies, Inc. develops non-lethal safety solutions for law enforcement, corrections, and private security sectors across North America and global markets. Its core products include remote restraint devices and training services designed to reduce use-of-force injuries and improve public safety outcomes.

TCRX vs WRAP — Head-to-Head

Bigger by revenue
TCRX
TCRX
1.8× larger
TCRX
$2.6M
$1.4M
WRAP
Growing faster (revenue YoY)
TCRX
TCRX
+223.7% gap
TCRX
286.0%
62.3%
WRAP
Higher net margin
WRAP
WRAP
614.2% more per $
WRAP
-280.9%
-895.1%
TCRX
More free cash flow
WRAP
WRAP
$29.5M more FCF
WRAP
$-2.7M
$-32.2M
TCRX
Faster 2-yr revenue CAGR
WRAP
WRAP
Annualised
WRAP
-2.5%
-9.7%
TCRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
TCRX
TCRX
WRAP
WRAP
Revenue
$2.6M
$1.4M
Net Profit
$-23.0M
$-3.9M
Gross Margin
52.3%
Operating Margin
-929.4%
-281.1%
Net Margin
-895.1%
-280.9%
Revenue YoY
286.0%
62.3%
Net Profit YoY
35.8%
48.1%
EPS (diluted)
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TCRX
TCRX
WRAP
WRAP
Q4 25
$2.6M
$1.4M
Q3 25
$2.5M
$1.5M
Q2 25
$3.1M
$1.0M
Q1 25
$2.2M
$765.0K
Q4 24
$865.0K
Q3 24
$1.0M
$593.0K
Q2 24
$1.6M
Q1 24
$1.5M
Net Profit
TCRX
TCRX
WRAP
WRAP
Q4 25
$-23.0M
$-3.9M
Q3 25
$-35.7M
$-2.8M
Q2 25
$-37.0M
$-3.7M
Q1 25
$-34.1M
$109.0K
Q4 24
$-7.6M
Q3 24
$-29.9M
$2.0M
Q2 24
$-385.0K
Q1 24
$117.0K
Gross Margin
TCRX
TCRX
WRAP
WRAP
Q4 25
52.3%
Q3 25
59.2%
Q2 25
48.1%
Q1 25
77.8%
Q4 24
47.4%
Q3 24
39.6%
Q2 24
62.6%
Q1 24
56.6%
Operating Margin
TCRX
TCRX
WRAP
WRAP
Q4 25
-929.4%
-281.1%
Q3 25
-1475.6%
-185.2%
Q2 25
-1256.6%
-282.2%
Q1 25
-1669.7%
-512.7%
Q4 24
-535.5%
Q3 24
-3109.8%
-611.5%
Q2 24
-201.5%
Q1 24
-280.4%
Net Margin
TCRX
TCRX
WRAP
WRAP
Q4 25
-895.1%
-280.9%
Q3 25
-1422.1%
-186.0%
Q2 25
-1201.3%
-368.3%
Q1 25
-1571.9%
14.2%
Q4 24
-878.3%
Q3 24
-2849.1%
335.6%
Q2 24
-24.5%
Q1 24
7.9%
EPS (diluted)
TCRX
TCRX
WRAP
WRAP
Q4 25
$-0.18
Q3 25
$-0.28
$-0.06
Q2 25
$-0.28
$-0.07
Q1 25
$-0.26
Q4 24
Q3 24
$-0.25
$0.04
Q2 24
$-0.02
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TCRX
TCRX
WRAP
WRAP
Cash + ST InvestmentsLiquidity on hand
$152.4M
$3.5M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$123.1M
$11.5M
Total Assets
$228.8M
$15.4M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TCRX
TCRX
WRAP
WRAP
Q4 25
$152.4M
$3.5M
Q3 25
$184.5M
$6.0M
Q2 25
$218.0M
$4.2M
Q1 25
$251.7M
$6.2M
Q4 24
$3.6M
Q3 24
$271.1M
$4.9M
Q2 24
$4.6M
Q1 24
$8.2M
Total Debt
TCRX
TCRX
WRAP
WRAP
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
Q1 25
$32.2M
Q4 24
Q3 24
$30.6M
Q2 24
Q1 24
Stockholders' Equity
TCRX
TCRX
WRAP
WRAP
Q4 25
$123.1M
$11.5M
Q3 25
$144.0M
$14.1M
Q2 25
$176.7M
$11.8M
Q1 25
$210.2M
$2.6M
Q4 24
$250.0K
Q3 24
$229.1M
$6.4M
Q2 24
$3.8M
Q1 24
$4.5M
Total Assets
TCRX
TCRX
WRAP
WRAP
Q4 25
$228.8M
$15.4M
Q3 25
$262.2M
$18.2M
Q2 25
$298.6M
$15.6M
Q1 25
$332.7M
$18.0M
Q4 24
$15.1M
Q3 24
$348.0M
$18.8M
Q2 24
$21.8M
Q1 24
$24.8M
Debt / Equity
TCRX
TCRX
WRAP
WRAP
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
Q1 25
0.15×
Q4 24
Q3 24
0.13×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TCRX
TCRX
WRAP
WRAP
Operating Cash FlowLast quarter
$-32.0M
$-2.7M
Free Cash FlowOCF − Capex
$-32.2M
$-2.7M
FCF MarginFCF / Revenue
-1253.3%
-190.3%
Capex IntensityCapex / Revenue
6.7%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-139.7M
$-10.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TCRX
TCRX
WRAP
WRAP
Q4 25
$-32.0M
$-2.7M
Q3 25
$-32.5M
$-2.6M
Q2 25
$-33.3M
$-1.9M
Q1 25
$-37.6M
$-3.1M
Q4 24
$-1.2M
Q3 24
$-27.9M
$330.0K
Q2 24
$-3.5M
Q1 24
$-3.7M
Free Cash Flow
TCRX
TCRX
WRAP
WRAP
Q4 25
$-32.2M
$-2.7M
Q3 25
$-33.9M
$-2.7M
Q2 25
$-34.5M
$-1.9M
Q1 25
$-39.1M
$-3.1M
Q4 24
$-1.2M
Q3 24
$-29.3M
Q2 24
$-3.5M
Q1 24
$-3.7M
FCF Margin
TCRX
TCRX
WRAP
WRAP
Q4 25
-1253.3%
-190.3%
Q3 25
-1349.6%
-181.1%
Q2 25
-1123.1%
-192.3%
Q1 25
-1801.8%
-401.4%
Q4 24
-139.5%
Q3 24
-2792.0%
Q2 24
-224.2%
Q1 24
-253.3%
Capex Intensity
TCRX
TCRX
WRAP
WRAP
Q4 25
6.7%
0.5%
Q3 25
56.8%
5.7%
Q2 25
41.6%
0.6%
Q1 25
70.6%
0.3%
Q4 24
0.1%
Q3 24
130.6%
0.0%
Q2 24
0.1%
Q1 24
0.9%
Cash Conversion
TCRX
TCRX
WRAP
WRAP
Q4 25
Q3 25
Q2 25
Q1 25
-28.16×
Q4 24
Q3 24
0.17×
Q2 24
Q1 24
-31.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons